Ischemic cardiomyopathy

Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years

Tuesday, September 14, 2021 - 2:10pm

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.

Key Points: 
  • Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.
  • A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia.
  • Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation.
  • This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable.

Maintaining Heart Function After a Heart Attack

Thursday, March 4, 2021 - 3:00pm

Heart attack not only causes instant chest pain and discomfort but also leads to a long-term ischemic injury to the heart that can result in a heart failure.In the process of myocardial ischemic infarction, an essential trace element copper is pushed out from the heart.

Key Points: 
  • Heart attack not only causes instant chest pain and discomfort but also leads to a long-term ischemic injury to the heart that can result in a heart failure.In the process of myocardial ischemic infarction, an essential trace element copper is pushed out from the heart.
  • Previous studies have demonstrated that repletion of copper to the copper-deficient ischemic heart can repair the damaged heart and facilitate recovery of heart function.
  • Genetic deletion of the COMMD1 gene in the heart blocked copper loss from the heart after ischemic insult.
  • Importantly, prevention of copper loss from the heart remarkably suppressed heart tissue death and preserved heart function.Dr.

Okayama University research: Skipping a beat -- a novel method to study heart attacks

Thursday, November 12, 2020 - 9:39am

Ischemic heart disease often leads to heart attacks and is the leading cause of death worldwide.

Key Points: 
  • Ischemic heart disease often leads to heart attacks and is the leading cause of death worldwide.
  • Scientists rely on animal models such as rats and mice to study ischemic heart disease.
  • The video can be accessed at: https://www.jove.com/t/61104/model-ischemic-heart-disease-video-based-co...
    Ischemic heart disease Ischemic heart disease is a fatal condition that stems from an inadequate blood supply to the heart muscles.
  • Ischemic heart disease is the leading cause of mortality worldwide, and accounts for 40% of heart diseaserelated deaths in Japan.

Okayama University research: Skipping a beat -- a novel method to study heart attacks

Thursday, November 12, 2020 - 9:32am

Ischemic heart disease often leads to heart attacks and is the leading cause of death worldwide.

Key Points: 
  • Ischemic heart disease often leads to heart attacks and is the leading cause of death worldwide.
  • Scientists rely on animal models such as rats and mice to study ischemic heart disease.
  • The video can be accessed at: https://www.jove.com/t/61104/model-ischemic-heart-disease-video-based-co...
    Ischemic heart disease Ischemic heart disease is a fatal condition that stems from an inadequate blood supply to the heart muscles.
  • Ischemic heart disease is the leading cause of mortality worldwide, and accounts for 40% of heart diseaserelated deaths in Japan.

InGeneron Announces Publication of Preclinical Results for its Cell Therapy in Chronic Ischemic Heart Failure

Thursday, October 31, 2019 - 12:03pm

InGeneron, Inc., a regenerative medicine and cell therapy company, today announced the publication of promising results in developing a novel treatment for chronic ischemic heart failure using its regenerative cell therapy platform.

Key Points: 
  • InGeneron, Inc., a regenerative medicine and cell therapy company, today announced the publication of promising results in developing a novel treatment for chronic ischemic heart failure using its regenerative cell therapy platform.
  • The publication, performed in a pig model for the study of chronic myocardial infarction, evidences for the first time that regeneration of the damaged tissue in the heart - responsible for chronic ischemic heart failure - is possible.
  • The findings represent an important step in research, laying the foundation for new frontiers on cardiac regeneration of chronic ischemic heart failure in human patients.
  • This gives hope that millions of patients suffering from chronic ischemic heart failure might benefit from rebuilding the heart with their own stem cells".

Ischemic Cardiomyopathy - Pipeline Insights, 2019 - ResearchAndMarkets.com

Wednesday, February 27, 2019 - 3:08pm

The "Ischemic Cardiomyopathy - Pipeline Insights, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ischemic Cardiomyopathy - Pipeline Insights, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Ischemic Cardiomyopathy - Pipeline Insight, 2019 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Ischemic Cardiomyopathy development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • The report covers pipeline activity across the complete product development cycle i.e.

Alterations in Copper Homeostasis in Ischemic Heart Disease

Wednesday, May 30, 2018 - 1:00pm

Myocardial ischemia occurs when blood flow to the heart is reduced and the heart muscle (myocardium) does not receive enough oxygen to function normally.

Key Points: 
  • Myocardial ischemia occurs when blood flow to the heart is reduced and the heart muscle (myocardium) does not receive enough oxygen to function normally.
  • It has been known for many years that patients with myocardial ischemia have elevated levels of copper in the blood.
  • Reduced copper levels in the ischemic heart suggest that ischemic injury may cause the heart to release copper into the blood.
  • As important, we found that a copper chaperone is involved in the release of myocardial copper.